Compare FPH & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | SGHT |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.0M | 395.5M |
| IPO Year | 2017 | 2021 |
| Metric | FPH | SGHT |
|---|---|---|
| Price | $5.76 | $7.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.23 |
| AVG Volume (30 Days) | 147.9K | ★ 307.2K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.55 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $193,904,000.00 | $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.07 |
| P/E Ratio | $4.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.56 | $2.03 |
| 52 Week High | $6.71 | $9.24 |
| Indicator | FPH | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 43.79 |
| Support Level | $5.39 | $7.28 |
| Resistance Level | $5.67 | $8.19 |
| Average True Range (ATR) | 0.14 | 0.60 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 100.00 | 10.48 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its three reportable segments are Valencia, San Francisco, and Great Park. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.